{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:33:03Z","timestamp":1794839583098,"version":"4.9.1"},"reference-count":165,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic sclerosis (SSc) is a complex, immune-mediated rheumatic disease characterised by excessive extracellular matrix deposition in the skin and internal organs. B cell infiltration into lesional sites such as the alveolar interstitium and small blood vessels, alongside the production of defined clinically relevant autoantibodies indicates that B cells play a fundamental role in the pathogenesis and development of SSc. This is supported by B cell and fibroblast coculture experiments revealing that B cells directly enhance collagen and extracellular matrix synthesis in fibroblasts. In addition, B cells from SSc patients produce large amounts of profibrotic cytokines such as IL-6 and TGF-\u03b2, which interact with other immune and endothelial cells, promoting the profibrotic loop. Furthermore, total B cell counts are increased in SSc patients compared with healthy donors and specific differences can be found in the content of na\u00efve, memory, transitional and regulatory B cell compartments. B cells from SSc patients also show differential expression of activation markers such as CD19 which may shape interactions with other immune mediators such as T follicular helper cells and dendritic cells. The key role of B cells in SSc is further supported by the therapeutic benefit of B cell depletion with rituximab in some patients. It is notable also that B cell signaling is impaired in SSc patients, and this could underpin the failure to induce tolerance in B cells as has been shown in murine models of scleroderma.<\/jats:p>","DOI":"10.3389\/fimmu.2022.999008","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:34:45Z","timestamp":1673847285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Dysregulated B cell function and disease pathogenesis in systemic sclerosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Claire F.","family":"Beesley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina R.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher E.","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizgar A.","family":"Mageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon H.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.005","article-title":"Systemic sclerosis: New evidence re\u2013enforces the role of b cells","volume":"15","author":"Sakkas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS\u20132013\u2013204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20136736(17)30933\u20139","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B5","article-title":"Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis","volume":"15","author":"Carwile LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.10.010","article-title":"The immunobiology of systemic sclerosis","volume":"38","author":"Gu","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13\u20132626","article-title":"Predictors of mortality and progression in scleroderma\u2013associated interstitial lung disease: A systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of systemic sclerosis associated interstitial lung disease","volume":"5","author":"Nihtyanova","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: A possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7555\/JBR.29.20150035","article-title":"Translating transitions \u2013 how to decipher peripheral human b cell development","volume":"29","author":"Bemark","year":"2015","journal-title":"J BioMed Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2016.00546\/BIBTEX","article-title":"Transitional b cells in early human b cell development \u2013 time to revisit the paradigm","volume":"7","author":"Martin","year":"2016","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075\u2013020\u201302383\u2013W","article-title":"Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis","volume":"23","author":"Fox","year":"2021","journal-title":"Arthritis Res Ther 2021 231"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.20274","article-title":"Altered blood b lymphocyte homeostasis in systemic sclerosis: Expanded naive b cells and diminished but activated memory b cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ART.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00496","article-title":"Systemic sclerosis patients present alterations in the expression of molecules involved in b\u2013cell regulation","volume":"6","author":"Soto","year":"2015","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40390","article-title":"Association of defective regulation of autoreactive interleukin\u20136\u2013Producing transitional b lymphocytes with disease in patients with systemic sclerosis","volume":"70","author":"Taher","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ART.41927","article-title":"Defective early b cell tolerance checkpoints in patients with systemic sclerosis allow the production of self\u2013antigen\u2013specific clones","volume":"74","author":"Glauzy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaci.2015.09.014","article-title":"In\u2013depth characterization of CD24highCD38high transitional human b cells reveals different regulatory profiles","volume":"137","author":"Simon","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.CYTOGFR.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.170.6.3263","article-title":"Activation of STAT3 by IL\u20136 and IL\u201310 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3","volume":"170","author":"Niemand","year":"2003","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.177.11.7880","article-title":"General nature of the STAT3\u2013activated anti\u2013inflammatory response","volume":"177","author":"Kasmi","year":"2006","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1213-9","article-title":"TIM\u20131 defines a human regulatory b cell population that is altered in frequency and function in systemic sclerosis patients","volume":"19","author":"Aravena","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory b cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2017.00053","article-title":"B cell homeostasis and functional properties are altered in an hypochlorous acid\u2013induced murine model of systemic sclerosis","volume":"8","author":"Sanges","year":"2017","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMMUNI.2015.04.005","article-title":"Regulatory b cells: Origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075\u2013019\u20131889\u20138\/FIGURES\/4","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long\u2013lasting changes in b cell homeostasis toward an anti\u2013inflammatory b cell cytokine pattern","volume":"21","author":"Gernert","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B29","article-title":"Reduced non\u2013switched memory b cell subsets cause imbalance in b cell repertoire in systemic sclerosis","author":"Simon","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEG170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS\u20132011\u2013200546","article-title":"Baseline characteristics and follow\u2013up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry","volume":"71","author":"Bae","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3899\/RHEUM.111133","article-title":"Clinical correlates of CENP\u2013a and CENP\u2013b antibodies in a large cohort of patients with systemic sclerosis","volume":"39","author":"Hudson","year":"2012","journal-title":"J Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10163757","article-title":"Role of the immune system elements in pulmonary arterial hypertension","volume":"10","author":"Tomaszewski","year":"2021","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1152\/AJPLUNG.00311.2016\/ASSET\/IMAGES\/LARGE\/ZH50041772100008.JPEG","article-title":"The mast cell\u2013b cell axis in lung vascular remodeling and pulmonary hypertension","volume":"312","author":"Breitling","year":"2017","journal-title":"Am J Physiol \u2013 Lung Cell Mol Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1165\/RCMB.2012\u20130077OC","article-title":"Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization","volume":"47","author":"Mizuno","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: Unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319870667","article-title":"The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma)","volume":"32","author":"Sen\u00e9cal","year":"2005","journal-title":"J Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ART.20515","article-title":"Direct binding of anti\u2013DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis","volume":"50","author":"H\u00e9nault","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.38219","article-title":"Prevalence of anti\u2013RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta\u2013analysis","volume":"66","author":"Sobanski","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"key":"B42","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti\u2013RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMLET.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol Lett"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075\u2013020\u201302360\u20133","article-title":"Scleroderma\u2013specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther 2020 221"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20132249.2009.04059.x","article-title":"Autoantibody\u2013mediated regulation of b cell responses by functional anti\u2013CD22 autoantibodies in patients with systemic sclerosis","volume":"159","author":"Odaka","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/J.1600\u20130625.2006.00485.X","article-title":"Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ\u2013specific autoimmune diseases","volume":"16","author":"Matsushita","year":"2007","journal-title":"Exp Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.159.8.3782","article-title":"The affinity threshold for human b cell activation via the antigen receptor complex is reduced upon co\u2013ligation of the antigen receptor with CD21 (CR2)","volume":"159","author":"Mongini","year":"1997","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0002\u20139440(10)63328\u20137","article-title":"B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight\u2013skin mouse","volume":"165","author":"Asano","year":"2004","journal-title":"Am J Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/J.1600\u2013065X.2009.00782.X","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1385\/IR:22:2\u20133:281","article-title":"CD19 regulates intrinsic b lymphocyte signal transduction and activation through a novel mechanism of processive amplification","volume":"22","author":"Fujimoto","year":"2000","journal-title":"Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/intimm\/dxs090","article-title":"Complement receptor type 1 (CR1, CD35) is a potent inhibitor of b\u2013cell functions in rheumatoid arthritis patients","volume":"25","author":"Kremlitzka","year":"2013","journal-title":"Int Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm132","article-title":"Physiological up\u2013regulation of inhibitory receptors fc RII and CR1 on memory b cells is lacking in SLE patients","volume":"20","author":"Isaak","year":"2008","journal-title":"Int Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELLIMM.2014.05.006","article-title":"The PD\u20131\/PD\u2013Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"B55","first-page":"1553","article-title":"Programmed cell death protein 1 and programmed death\u2013ligand 1 are expressed on the surface of some small\u2013cell lung cancer lines","volume":"5","author":"Yamane","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ART.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/J.IMLET.2018.01.002","article-title":"Pathogenic roles of b lymphocytes in systemic sclerosis","volume":"195","author":"Yoshizaki","year":"2018","journal-title":"Immunol Lett"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20138138.13339","article-title":"Serum levels of soluble programmed death\u20131 and programmed death ligand\u20131 in systemic sclerosis: Association with extent of skin sclerosis","volume":"43","author":"Yanaba","year":"2016","journal-title":"J Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.61","article-title":"TLR signaling in b\u2013cell development and activation","volume":"10","author":"Hua","year":"2012","journal-title":"Cell Mol Immunol 2013 102"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1719720","article-title":"The role of TLR4 on b cell activation and anti\u2013\u03b22GPI antibody production in the antiphospholipid syndrome","volume":"2016","author":"Cheng","year":"2016","journal-title":"J Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.IMLET.2017.09.011","article-title":"Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy","volume":"195","author":"Bhattacharyya","year":"2018","journal-title":"Immunol Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2017.00775\/BIBTEX","article-title":"TLR7\/TLR9\u2013 and b cell receptor\u2013signaling crosstalk: Promotion of potentially dangerous b cells","volume":"8","author":"Suthers","year":"2017","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.01243\/BIBTEX","article-title":"High TLR7 expression drives the expansion of CD19+CD24HiCD38hi transitional b cells and autoantibody production in SLE patients","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/S13353\u2013017\u20130415\u20134","article-title":"Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"59","author":"Vre\u0107a","year":"2018","journal-title":"J Appl Genet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10409238.2016.1215288","article-title":"The PI3K pathway in b cell metabolism","volume":"51","author":"Jellusova","year":"2016","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2012.00228\/BIBTEX","article-title":"Akt and mTOR in b cell activation and differentiation","volume":"3","author":"Limon","year":"2012","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365\u20132567.2003.01756.X","article-title":"B\u2013cell antigen\u2013receptor signalling in lymphocyte development","volume":"110","author":"Wang","year":"2003","journal-title":"Immunology"},{"key":"B68","article-title":"Association study of b\u2013cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis","volume":"29","author":"Dawidowicz","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ART.24885","article-title":"BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4","volume":"60","author":"Dieud\u00e9","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598\u2013018\u201319460\u20135","article-title":"PI3K induces b\u2013cell development and regulates b cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/ARD.2009.127928","article-title":"Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population","volume":"69","author":"Dieud\u00e9","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ART.34490","article-title":"Brief report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity","volume":"64","author":"Koumakis","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/J.IMMUNI.2010.07.017","article-title":"The ubiquitin modifying enayme A20 restricts b cell survival and prevents autoimmunity","volume":"33","author":"Tavares","year":"2010","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2009.08.041","article-title":"PI3 kinase signals BCR\u2013dependent mature b cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/HMG\/DDS099","article-title":"Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow\u2013up","volume":"21","author":"Martin","year":"2012","journal-title":"Hum Mol Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2009.08.014","article-title":"Association of the C8orf13\u2013BLK region with systemic sclerosis in north\u2013American and European populations","volume":"34","author":"Gourh","year":"2010","journal-title":"J Autoimmun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ART.23601","article-title":"The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case\u2013control study of European caucasians and a meta\u2013analysis","volume":"58","author":"Dieud\u00e9","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PCBI.1004005","article-title":"Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms","volume":"11","author":"Mahoney","year":"2015","journal-title":"PloS Comput Biol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS22062877","article-title":"Analysis of PI3K pathway associated molecules reveals dysregulated innate and adaptive functions of b cells in early diffuse cutaneous systemic sclerosis","volume":"22","author":"Simon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/40.11.1315","article-title":"CD180 (RP105) in rheumatic diseases","volume":"40","author":"Koarada","year":"2001","journal-title":"Rheumatology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.1100198","article-title":"Anti\u2013CD180 (RP105) activates b cells to rapidly produce polyclonal ig via a T cell and MyD88\u2013independent pathway","volume":"187","author":"Chaplin","year":"2011","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.1900549\/\u2013\/DCSUPPLEMENTAL","article-title":"Targeting antigens to CD180 but not CD40 programs immature and mature b cell subsets to become efficient APCs","volume":"203","author":"Roe","year":"2019","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20246152","article-title":"Toll\u2013like receptor mediated activation of natural autoantibody producing b cell subpopulations in an autoimmune disease model","volume":"20","author":"Erd\u0151\u2013Bony\u00e1r","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8370","article-title":"An analysis of abnormalities in the b cell receptor repertoire in patients with systemic sclerosis using high\u2013throughput sequencing","volume":"2020","author":"Shi","year":"2020","journal-title":"PeerJ"},{"key":"B85","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/ICB.2015.57","article-title":"BCR repertoire sequencing: different patterns of b cell activation after two meningococcal vaccines","volume":"93","author":"Galson","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.IMMUNI.2013.10.022","article-title":"Interleukin\u20136 signaling drives fibrosis in unresolved inflammation","volume":"40","author":"Fielding","year":"2014","journal-title":"Immunity"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20170580","article-title":"B cell\u2013derived IL\u20136 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-020-02289-W","article-title":"Transitional b cells involved in autoimmunity and their impact on neuroimmunological diseases","volume":"18","author":"Zhou","year":"2020","journal-title":"J Transl Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1182\/BLOOD\u20132009\u201307\u2013230631","article-title":"IL\u20136 increases b\u2013cell IgG production in a feed\u2013forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production","volume":"115","author":"Maeda","year":"2010","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05886.x","article-title":"Macrophage depletion decreases IgG anti\u2013DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL\u20136","volume":"91","author":"Alarcon\u2013Riquelme","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/J.FEBSLET.2012.03.063","article-title":"Dynamics of TGF\u2013\u03b2\/Smad signaling","volume":"586","author":"Zi","year":"2012","journal-title":"FEBS Lett"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0057474","article-title":"TGF\u2013\u03b2\u2013Elicited induction of tissue inhibitor of metalloproteinases (TIMP)\u20133 expression in fibroblasts involves complex interplay between Smad3, p38\u03b1, and ERK1\/2","volume":"8","author":"Leivonen","year":"2013","journal-title":"PloS One"},{"key":"B93","article-title":"Upregulated expression of transforming growth factor\u2013beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis","volume":"29","author":"Kubo","year":"2002","journal-title":"J Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL\u201310","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol 2002 310"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/J.AUTREV.2017.10.015","article-title":"Altered b lymphocyte homeostasis and functions in systemic sclerosis","volume":"17","author":"Forestier","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV.IMMUNOL.21.120601.141142","article-title":"IL\u201313 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.3.1094","article-title":"IL\u201313 induces proliferation, ig isotype switching, and ig synthesis by immature human fetal b cells","volume":"152","author":"Punnonen","year":"1994","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/INTIMM\/5.6.657","article-title":"IL\u201313 induces proliferation and differentiation of human b cells activated by the CD40 ligand","volume":"5","author":"Cocks","year":"1993","journal-title":"Int Immunol"},{"key":"B99","article-title":"Elevated serum levels of interleukin 4 (IL\u20134), IL\u201310, and IL\u201313 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.0903306","article-title":"IL\u201333 induces IL\u201313\u2013Dependent cutaneous fibrosis","volume":"184","author":"Rankin","year":"2010","journal-title":"J Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02871\/BIBTEX","article-title":"Interleukin\u201333 contributes toward loss of tolerance by promoting b\u2013Cell\u2013Activating factor of the tumor\u2013Necrosis\u2013Factor family (BAFF)\u2013dependent autoantibody production","volume":"9","author":"Rose","year":"2018","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.171.4.1642","article-title":"Cutting edge: The b cell chemokine CXC chemokine ligand 13\/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and peyer\u2019s patches and affects b cell trafficking across high endothelial venules","volume":"171","author":"Ebisuno","year":"2003","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.1900790","article-title":"TNF\u2013\u03b1 and IL\u201310 control CXCL13 expression in human macrophages","volume":"204","author":"Bellamri","year":"2020","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20132004\u201302\u20130701","article-title":"Monocyte\u2013like and mature macrophages produce CXCL13 (B cell\u2013attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis","volume":"104","author":"Carlsen","year":"2004","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/J.0105\u20132896.2005.00219.X","article-title":"The role of BAFF in immune function and implications for autoimmunity","volume":"204","author":"Kalled","year":"2005","journal-title":"Immunol Rev"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for b cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.COI.2008.03.015","article-title":"BAFF and the plasticity of peripheral b cell tolerance","volume":"20","author":"Stadanlick","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.AAS9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector b cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci Adv"},{"key":"B109","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis b lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2020.102526","article-title":"Bi\u2013directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis","volume":"113","author":"Worrell","year":"2020","journal-title":"J Autoimmun"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/S10067\u2013021\u201305665\u2013Z","article-title":"B cells in systemic sclerosis: from pathophysiology to treatment","volume":"40","author":"Melissaropoulos","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B112","first-page":"493","article-title":"Tight\u2013skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton","volume":"82","author":"Green","year":"1976","journal-title":"Am J Pathol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI15078","article-title":"CD19\u2013dependent b lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight\u2013skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.JID.5700919","article-title":"BAFF antagonist attenuates the development of skin fibrosis in tight\u2013skin mice","volume":"127","author":"Matsushita","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/ART.23995","article-title":"CD19 regulates the development of bleomycin\u2013induced pulmonary fibrosis in a mouse model","volume":"58","author":"Komura","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000082087","article-title":"The CD19\u2013CD21 signal transduction complex of b lymphocytes regulates the balance between health and autoimmune disease: Systemic sclerosis as a model system","volume":"8","author":"Tedder","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/ART.30539","article-title":"Immunization with DNA topoisomerase I and freund\u2019s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin\u20136 signaling","volume":"63","author":"Yoshizaki","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type\u2013specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270607","article-title":"Lymphocytes in the skin of patients with progressive systemic sclerosis","volume":"27","author":"Roumm","year":"1984","journal-title":"Arthritis Rheum"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075\u2013018\u20131569\u20130","article-title":"Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression","volume":"20","author":"Bosello","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS\u20132019\u2013215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis\u2013associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.1403246\/\u2013\/DCSUPPLEMENTAL","article-title":"IL\u201310 + innate\u2013like b cells are part of the skin immune system and require \u03b14\u03b21 integrin to migrate between the peritoneum and inflamed skin","volume":"196","author":"Geherin","year":"2016","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis\u2013associated interstitial lung disease: How to incorporate two food and drug administration\u2013approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA055120\/SUPPL_FILE\/NEJM_TASHKIN_2655SA1.PDF","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4049\/jimmunol.204.Supp.238.16","article-title":"Single\u2013cell analysis of autoreactive b cells in patients with systemic sclerosis revealed that responses to therapy are determined by effector and regulatory b cell balance","volume":"204","author":"Ebata","year":"2020","journal-title":"J Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20132600(16)30152\u20137","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma\u2013related interstitial lung disease (SLS II): a randomised controlled, double\u2013blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162\u20133109(00)00188\u20130","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213\u20132600(20)30330\u20131","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis\u2013associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B130","article-title":"Background mycophenolate (MMF) treatment is associated with improved outcomes in a phase 3 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc)","author":"Spiera","year":"2021","journal-title":"ACR Meet Abstr"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704892","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"35","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant 2005 359"},{"key":"B132","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140\u20136736(11)60982\u20133","article-title":"Autologous non\u2013myeloablative haemopoietic stem\u2013cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open\u2013label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMOA1703327","article-title":"Myeloablative autologous stem\u2013cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"Van Laar","year":"2014","journal-title":"JAMA"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAB257","article-title":"Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory b cells in systemic sclerosis patients","volume":"60","author":"Lima\u2013J\u00fanior","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL\u20136 modulation in an up to thirty\u2013six months follow\u2013up open\u2013label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B137","article-title":"Effect of long\u2013term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi\u2013Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/ARD.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: An open\u2013label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3899\/JRHEUM.120778","article-title":"Two\u2013year results of an open pilot study of a 2\u2013treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEP093","article-title":"Experience with rituximab in scleroderma: results from a 1\u2013year, proof\u2013of\u2013principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMARTHRIT.2016.10.003","article-title":"A multicenter, open\u2013label, comparative study of b\u2013cell depletion therapy with rituximab for systemic sclerosis\u2013associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B143","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. a single\u2013centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEY213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20132013\u2013204522","article-title":"Effects and safety of rituximab in systemic sclerosis: An analysis from the European scleroderma trial and research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16206","article-title":"Percentage of residual b cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis\u2013associated interstitial lung disease","volume":"49","author":"Ebata","year":"2022","journal-title":"J Dermatol"},{"key":"B148","article-title":"Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab","volume":"33","author":"Fraticelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20132018\u2013214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: A systematic review and meta\u2013analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatol (United Kingdom)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of rituximab in systemic sclerosis: A systematic review and meta\u2013analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S2665\u20139913(21)00107\u20137","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double\u2013blind, investigator\u2013initiated, randomised, placebo\u2013controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063\u2013017\u20132016\u20132","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): Study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150105.C1","article-title":"Specific antinuclear antibody level changes after b cell depletion therapy in systemic sclerosis are associated with improvement of skin thickening","volume":"43","author":"Bonroy","year":"2016","journal-title":"J Rheumatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20138138.12461","article-title":"Successful experience of rituximab therapy for systemic sclerosis\u2013associated interstitial lung disease with concomitant systemic lupus erythematosus","volume":"41","author":"Sumida","year":"2014","journal-title":"J Dermatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.00835\/BIBTEX","article-title":"Targeting b cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/ART.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI\u2013551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13075\u2013016\u20131021\u20132\/TABLES\/5","article-title":"Safety and tolerability of an anti\u2013CD19 monoclonal antibody, MEDI\u2013551, in subjects with systemic sclerosis: A phase I, randomized, placebo\u2013controlled, escalating single\u2013dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9010077","article-title":"Is there a future for anti\u2013CD38 antibody therapy in systemic autoimmune diseases","volume":"9","author":"Benfaremo","year":"2020","journal-title":"Cells"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/ART.40358\/ABSTRACT","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: Results of a randomized, double\u2013blind, placebo\u2013controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20132600(20)30318\u20130","article-title":"Tocilizumab in systemic sclerosis: a randomised, double\u2013blind, placebo\u2013controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20136736(16)00232\u20134\/ATTACHMENT\/99F33BB7\u201393E6\u20134708\u201394C8\u201306E25B85693D\/MMC1.PDF","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.871861","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: A 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.999008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:34:57Z","timestamp":1673847297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.999008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":165,"alternative-id":["10.3389\/fimmu.2022.999008"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.999008","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"article-number":"999008"}}